Objective:
To examine how personalized corneal cross-linking (CXL) is transforming clinical practice for corneal ectatic diseases, emphasizing its significance in improving patient outcomes.
Key Findings:
- Epi-on CXL protocols have been developed to minimize risks while maintaining epithelial integrity, showing promise in clinical outcomes.
- Corneal optimization before cataract surgery can enhance IOL calculation accuracy, leading to better refractive outcomes.
- Customized CXL combined with excimer laser treatment can significantly improve visual outcomes in irregular corneas, demonstrating the effectiveness of personalized approaches.
Interpretation:
Personalized CXL approaches allow for tailored treatment strategies that enhance both corneal stability and visual quality across various patient scenarios, ultimately improving patient outcomes.
Limitations:
- Epi-on CXL may still lag behind epi-off in certain biomechanical effects, and further research is needed to fully understand its long-term efficacy.
- Clinical outcomes depend on careful patient selection and adherence to advanced protocols, which may pose challenges in real-world settings.
Conclusion:
Personalized CXL represents a significant advancement in treating corneal ectatic diseases, offering improved safety and visual outcomes, and highlighting its transformative potential in clinical practice.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
